Cellid셀리드

Cellid remains loss-making with heavy spending, and its share price has fallen sharply over the past year.

Cellid is a Korean biopharma developer with cancer immunotherapy and infectious disease vaccine platforms, none of which are commercial yet, plus a contract manufacturing unit in Seongnam. On trailing twelve-month figures to H1 2026 it reported revenue of ₩10.4B against an operating loss of ₩10.3T-scale magnitude in won terms, shown here as roughly -₩10.3B, and free cash flow of about -₩22.9B. The share price closed at ₩2,125 on 27 October 2026, down 41.5% over one year but up 19.6% over three months.

What stands out

• Trailing revenue is about ₩10.4B, while operating loss is about ₩10.3B and net loss about ₩27.4B, so the operating margin is -99.3% and net margin -262.8%.
• Borrowings of about ₩33.6B exceed cash of about ₩13.0B, and liabilities are 80.4% of equity.
• Annual revenue rose to ₩8.8B in 2025 from ₩4.2B in 2024, but operating losses have stayed above ₩11B every year since 2021.
• Price-to-book is 1.2 and price-to-sales is 6, with no P/E because the company is loss-making, and no dividend is paid.
• Foreign ownership fell from 1.5% to 1.2% over 60 days, and 20-day flows show retail net selling of about ₩4.3B while foreign investors were net buyers of about ₩21.6M.
• Recent filings include two lawsuit-related entries dated 28 October 2026, a shareholders' meeting notice, and several amended stock purchase option grant notices. The data does not say what the lawsuits concern.

What to watch

• The shareholders' meeting called in the 21 October filings, including its agenda, which is not detailed in the data.
• Details and outcome of the lawsuit filings dated 28 October 2026, which the data does not describe.
• Whether the company can fund its losses and debt; the data does not include guidance, clinical timelines or upcoming results dates.